Autres langues Fortress Biotech, Inc.

Actions

FBIO

US34960Q3074

Produits pharmaceutiques

Temps réel estimé Cboe BZX 18:25:11 08/09/2026			Varia. 5j.	Varia. 1 janv.
2,715 ^USD	-0,18%		+1,31%	-25,82%

13/08	Fortress Biotech, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
13/08	Transcript : Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Autres langues

14:01	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
13/08	Fortress Biotech: Q2 Earnings Snapshot
13/08	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
13/08	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
12/08	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
05/08	Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
28/07	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics $130 Million Series B Financing
27/07	Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
19/05	Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference
18/05	Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
14/05	Fortress Biotech: Q1 Earnings Snapshot
14/05	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
14/05	Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
13/05	Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
06/05	Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
04/05	Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
21/04	Journey Medical Corporation secures contract with third major GPO for Emrosi
21/04	Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
31/03	Fortress Biotech: Q4 Earnings Snapshot
31/03	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
31/03	Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
30/03	Fortress Biotech Unit Closes $205 Million PRV Sale
30/03	Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
25/03	Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
18/03	Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026